Emergent BioSolutions

www.emergentbiosolutions.com

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

EMERGENT BIOSOLUTIONS COMPLETES ACQUISITION OF EXCLUSIVE WORLDWIDE RIGHTS TO TEMBEXA® FIRST FDA-APPROVED SMALLPOX ORAL ANTIVIRAL FOR ALL AGES

TEMBEXA and Smallpox | September 27, 2022

news image

Emergent BioSolutions Inc. announced that it has completed its acquisition of exclusive worldwide rights to TEMBEXA® the first oral antiviral approved by the U.S. Food and Drug Administration for all age groups for the treatment of smallpox, from Chimerix. TEMBEXA was approved in June 2021 and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. The completion of the acquisition follows the satisfaction or waiver by the ...

Read More

EMERGENT BIOSOLUTIONS ANNOUNCES INITIATION OF PHASE 3 CINICAL TRIAL OF HYPERIMMUNE INTRAVENOUS IMMUNOGLOBULIN TO TREAT COVID-19 PATIENTS

Emergent BioSolutions | October 09, 2020

news image

NIAID has initiated a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), as a potential treatment in adult patients hospitalized with COVID-19. Emergent is planning additional clinical trials to evaluate COVID-HIG for potential use in other patient populations or individuals at high risk of exposure. Emergent BioSolutions, Inc. Inc. (NYSE:EBS) today announced the initia...

Read More

EMERGENT BIOSOLUTIONS AND VALNEVA’S ZIKA VACCINE TURNS UP POSITIVE EARLY-PHASE DATA

Questex LLC | November 20, 2018

news image

A Zika vaccine candidate co-developed by Emergent BioSolutions and Valneva has turned up positive early-stage results, laying the groundwork for a potential technology transfer to Emergent. The alum-adjuvanted, inactivated vaccine candidate, dubbed VLA1601, was found to be safe in a phase 1 trial, meeting its primary endpoint. It also induced immune responses, as neutralizing antibodies against the Zika virus were observed in a dose- and schedule-dependent way, the pair reported on Monday. Seroc...

Read More

EMERGENT BIOSOLUTIONS SELECTS AXIOM FUSION ECLINICAL SUITE AS ITS GLOBAL ECLINICAL SUITE

BioSpace | March 04, 2020

news image

Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is pleased to announce its engagement with Emergent BioSolutions, Inc. (NYSE: EBS), a global life sciences company whose mission is to protect and enhance life by providing specialty products and contract development and manufacturing services that address public health threats....

Read More
news image

Cell and Gene Therapy

EMERGENT BIOSOLUTIONS COMPLETES ACQUISITION OF EXCLUSIVE WORLDWIDE RIGHTS TO TEMBEXA® FIRST FDA-APPROVED SMALLPOX ORAL ANTIVIRAL FOR ALL AGES

TEMBEXA and Smallpox | September 27, 2022

Emergent BioSolutions Inc. announced that it has completed its acquisition of exclusive worldwide rights to TEMBEXA® the first oral antiviral approved by the U.S. Food and Drug Administration for all age groups for the treatment of smallpox, from Chimerix. TEMBEXA was approved in June 2021 and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. The completion of the acquisition follows the satisfaction or waiver by the ...

Read More
news image

EMERGENT BIOSOLUTIONS ANNOUNCES INITIATION OF PHASE 3 CINICAL TRIAL OF HYPERIMMUNE INTRAVENOUS IMMUNOGLOBULIN TO TREAT COVID-19 PATIENTS

Emergent BioSolutions | October 09, 2020

NIAID has initiated a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), as a potential treatment in adult patients hospitalized with COVID-19. Emergent is planning additional clinical trials to evaluate COVID-HIG for potential use in other patient populations or individuals at high risk of exposure. Emergent BioSolutions, Inc. Inc. (NYSE:EBS) today announced the initia...

Read More
news image

EMERGENT BIOSOLUTIONS AND VALNEVA’S ZIKA VACCINE TURNS UP POSITIVE EARLY-PHASE DATA

Questex LLC | November 20, 2018

A Zika vaccine candidate co-developed by Emergent BioSolutions and Valneva has turned up positive early-stage results, laying the groundwork for a potential technology transfer to Emergent. The alum-adjuvanted, inactivated vaccine candidate, dubbed VLA1601, was found to be safe in a phase 1 trial, meeting its primary endpoint. It also induced immune responses, as neutralizing antibodies against the Zika virus were observed in a dose- and schedule-dependent way, the pair reported on Monday. Seroc...

Read More
news image

EMERGENT BIOSOLUTIONS SELECTS AXIOM FUSION ECLINICAL SUITE AS ITS GLOBAL ECLINICAL SUITE

BioSpace | March 04, 2020

Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is pleased to announce its engagement with Emergent BioSolutions, Inc. (NYSE: EBS), a global life sciences company whose mission is to protect and enhance life by providing specialty products and contract development and manufacturing services that address public health threats....

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us